Design Therapeutics, Inc.
corporate_fare Company Profile
Design Therapeutics, Inc. (NASDAQ:DSGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for DSGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for DSGN spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Design Therapeutics 10-Q: Q3 Loss $20.3M, $208.6M Cash, ATM Upsized to $200M
- Design Therapeutics Reports Q2 2026 Results, RESTORE-FA Modifications, and Pipeline Progress
- Design Therapeutics Modifies RESTORE-FA Trial, Initiates DT-818 Dosing, Reports Q2 Cash of $207.4M
- Design Therapeutics Reports Positive Phase 1/2 DT-216P2 Data in Friedreich Ataxia, Plans Registrational Path
- DT-216P2 Trial Shows Significant Clinical Improvements in Friedreich Ataxia; Design Therapeutics Plans Registrational Development
Financial Snapshot
Short Interest & Short Volume
16.22 days to coverFINRA reported short interest of 6,311,677 shares in DSGN as of the October 30, 2026 settlement, a 5.1% decrease from the prior period — about 16.2 days to cover at its recent average daily volume. On November 20, 2026, 72.7% of DSGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DSGN, detected from its recent SEC filings · based on capital-structure filings through 2026-11-04.
New $300M Universal Shelf Filed · Stacks on $200M ATM Upsizing
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →